PD-L1-specific T cells

Shamaila Munir Ahmad; Troels Holz Borch; Morten Hansen; Mads Hald Andersen

doi:10.1007/s00262-015-1783-4

PD-L1-specific T cells

Shamaila Munir Ahmad, Troels Holz Borch, Morten Hansen, Mads Hald Andersen^*

^*Corresponding author af dette arbejde

Glycomics Program

12 Citationer (Scopus)

Abstract

Recently, there has been an increased focus on the immune checkpoint protein PD-1 and its ligand PD-L1 due to the discovery that blocking the PD-1/PD-L1 pathway with monoclonal antibodies elicits striking clinical results in many different malignancies. We have described naturally occurring PD-L1-specific T cells that recognize both PD-L1-expressing immune cells and malignant cells. Thus, PD-L1-specific T cells have the ability to modulate adaptive immune reactions by reacting to regulatory cells. Thus, utilization of PD-L1-derived T cell epitopes may represent an attractive vaccination strategy for targeting the tumor microenvironment and for boosting the clinical effects of additional anticancer immunotherapy. This review summarizes present information about PD-L1 as a T cell antigen, depicts the initial findings about the function of PD-L1-specific T cells in the adjustment of immune responses, and discusses future opportunities.

Originalsprog	Engelsk
Tidsskrift	Cancer Immunology, Immunotherapy
Vol/bind	65
Udgave nummer	7
Sider (fra-til)	797-804
Antal sider	8
ISSN	0340-7004
DOI	https://doi.org/10.1007/s00262-015-1783-4
Status	Udgivet - jul. 2016

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1007/s00262-015-1783-4

Citationsformater

@article{90b484765bbd4f80b836b94ba5c92128,

title = "PD-L1-specific T cells",

abstract = "Recently, there has been an increased focus on the immune checkpoint protein PD-1 and its ligand PD-L1 due to the discovery that blocking the PD-1/PD-L1 pathway with monoclonal antibodies elicits striking clinical results in many different malignancies. We have described naturally occurring PD-L1-specific T cells that recognize both PD-L1-expressing immune cells and malignant cells. Thus, PD-L1-specific T cells have the ability to modulate adaptive immune reactions by reacting to regulatory cells. Thus, utilization of PD-L1-derived T cell epitopes may represent an attractive vaccination strategy for targeting the tumor microenvironment and for boosting the clinical effects of additional anticancer immunotherapy. This review summarizes present information about PD-L1 as a T cell antigen, depicts the initial findings about the function of PD-L1-specific T cells in the adjustment of immune responses, and discusses future opportunities.",

keywords = "Anti-Tregs, Cancer vaccines, CITIM 2015, PD-L1, PD-L1-specific T cells",

author = "Ahmad, {Shamaila Munir} and Borch, {Troels Holz} and Morten Hansen and Andersen, {Mads Hald}",

year = "2016",

month = jul,

doi = "10.1007/s00262-015-1783-4",

language = "English",

volume = "65",

pages = "797--804",

journal = "Cancer Immunology, Immunotherapy",

issn = "0340-7004",

publisher = "Springer",

number = "7",

}

TY - JOUR

T1 - PD-L1-specific T cells

AU - Ahmad, Shamaila Munir

AU - Borch, Troels Holz

AU - Hansen, Morten

AU - Andersen, Mads Hald

PY - 2016/7

Y1 - 2016/7

N2 - Recently, there has been an increased focus on the immune checkpoint protein PD-1 and its ligand PD-L1 due to the discovery that blocking the PD-1/PD-L1 pathway with monoclonal antibodies elicits striking clinical results in many different malignancies. We have described naturally occurring PD-L1-specific T cells that recognize both PD-L1-expressing immune cells and malignant cells. Thus, PD-L1-specific T cells have the ability to modulate adaptive immune reactions by reacting to regulatory cells. Thus, utilization of PD-L1-derived T cell epitopes may represent an attractive vaccination strategy for targeting the tumor microenvironment and for boosting the clinical effects of additional anticancer immunotherapy. This review summarizes present information about PD-L1 as a T cell antigen, depicts the initial findings about the function of PD-L1-specific T cells in the adjustment of immune responses, and discusses future opportunities.

AB - Recently, there has been an increased focus on the immune checkpoint protein PD-1 and its ligand PD-L1 due to the discovery that blocking the PD-1/PD-L1 pathway with monoclonal antibodies elicits striking clinical results in many different malignancies. We have described naturally occurring PD-L1-specific T cells that recognize both PD-L1-expressing immune cells and malignant cells. Thus, PD-L1-specific T cells have the ability to modulate adaptive immune reactions by reacting to regulatory cells. Thus, utilization of PD-L1-derived T cell epitopes may represent an attractive vaccination strategy for targeting the tumor microenvironment and for boosting the clinical effects of additional anticancer immunotherapy. This review summarizes present information about PD-L1 as a T cell antigen, depicts the initial findings about the function of PD-L1-specific T cells in the adjustment of immune responses, and discusses future opportunities.

KW - Anti-Tregs

KW - Cancer vaccines

KW - CITIM 2015

KW - PD-L1

KW - PD-L1-specific T cells

U2 - 10.1007/s00262-015-1783-4

DO - 10.1007/s00262-015-1783-4

M3 - Review

C2 - 26724936

AN - SCOPUS:84952646591

SN - 0340-7004

VL - 65

SP - 797

EP - 804

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

IS - 7

ER -

PD-L1-specific T cells

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater